<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Higher-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are similar pathobiologically to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), particularly in older adults </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> therapies thus may have activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the current study, phase 2 study data of <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> (ATO) and gemtuzumab ozogamicin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>) in CD33-positive patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> (sAML) were presented </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Between June 2004 and February 2006, 30 patients with higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or sAML received ATO (at a dose of 0.25 mg/kg intravenously for 5 days during Week 1, then twice weekly during Weeks 2-12) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> (at a dose of 3 mg/m(2) on Day 8) for 1 or 2 cycles of 12 weeks each </plain></SENT>
<SENT sid="4" pm="."><plain>The primary endpoint was response as per <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> International Working Group (IWG) criteria </plain></SENT>
<SENT sid="5" pm="."><plain>Adverse events were collected throughout treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Patients were followed for a minimum of 3 years for survival </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The median patient age was 69 years </plain></SENT>
<SENT sid="8" pm="."><plain>A total of 18 patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 12 had sAML, and 19 had been previously treated </plain></SENT>
<SENT sid="9" pm="."><plain>Seventeen patients (57%) completed â‰¥1 cycle, and 7 patients (23%) completed 2 cycles </plain></SENT>
<SENT sid="10" pm="."><plain>IWG responses occurred in 9 patients (30%) according to IWG <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> criteria (including 2 of 7 patients who failed hypomethylating agents) and 3 of 12 AML patients (25%) according to IWG <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> criteria </plain></SENT>
<SENT sid="11" pm="."><plain>Grade 3/4 (according to National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute Common Toxicity Criteria [version 3.0]) <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> occurred in 47% of patients, <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in 63%, and <z:hpo ids='HP_0001903'>anemia</z:hpo> in 37% of patients </plain></SENT>
<SENT sid="12" pm="."><plain>The median overall survival was 9.7 months (28.6 months in responders and 7.6 months in nonresponders; P &lt;.001) </plain></SENT>
<SENT sid="13" pm="."><plain>Patients who completed 2 cycles of therapy spent a median of 13 days in the hospital </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Combination therapy with ATO and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> was found to have acceptable response rates and toxicity, and may be a viable treatment option to standard induction therapy, particularly for patients who fail therapy with hypomethylating agents </plain></SENT>
</text></document>